Gelteq Ltd (GELS) stock
Close on Nov 12, 2026Market cap $4.08MP/E –Yield –
Gelteq Ltd reported revenue of A$165.65K for fiscal 2025. Free cash flow was -A$5.52M. At the latest close the market valued the company at A$5.93M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- A$5.93M
- P/E ratio
- –
- Price to sales
- 35.82
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -93.12%
Fundamentals
- Revenue
- A$165.65K
- EPS, diluted
- -0.72 AUD
- Free cash flow
- -A$5.52M
Trading
- Previous close
- $0.42
- Open
- $0.41
- Day's range
- $0.38 – $0.41
- Volume
- 24,909
- Average volume (20 days)
- 76,902
- Beta (5 years)
- 2.53
- RSI (14 days)
- 31.1
- Volatility (1 year)
- 229.1%
- Relative volume
- 0.01×
- WACC
- 14.8%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GELS | S&P 500 | Difference | GELS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.3% | -2.7% | −19.6 pts | ||
| 3 months | -33.3% | -1.7% | −31.5 pts | ||
| Year to date | -52.4% | +11.9% | −64.3 pts | ||
| 1 year | -64.1% | +12.0% | −76.1 pts |
Four years at a glance
Fiscal years 2022 to 2025, AUD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Gelteq filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Gelteq
Pharmaceutical Preparations
Gelteq Limited is an Australian clinical and consumer product company that develops and commercializes edible gels and gel-based dosage forms. The company designs gel formulations for multiple vertical markets, offering products across categories ranging from food-grade supplements to pharmaceutical applications that incorporate active pharmaceutical ingredients. Gelteq supplies its products and delivery technologies to corporate partners, commercial distributors, and end consumers across health, sports supplement, and therapeutic areas.
Company profile, executives and historyGelteq stock: common questions
What is Gelteq's stock price?
GELS closed at $0.38 on Nov 12, 2026, down 9.48% on the day.
What is Gelteq's market cap?
Gelteq was worth $4.08M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is GELS's P/E ratio?
Gelteq lost money over fiscal 2025 (diluted EPS -0.72 AUD), so it has no meaningful P/E ratio.
How much revenue does Gelteq make?
Gelteq reported revenue of A$165.65K for fiscal 2025.
Does Gelteq pay a dividend?
No. Gelteq has not paid a cash dividend over the last twelve months.
How has GELS stock performed over the past year?
Including dividends, GELS returned -64.1% over the past year, against +12.0% for the S&P 500.
Who are Gelteq's competitors?
Companies most similar to Gelteq by business, industry and size include LEXX, HIND, IXHL, CLNN, ASBP.
See a number that looks wrong?